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OBJECTIVE. To assess the relative importance of independent risk factors for peripheral intravenous catheter (PIVC) failure. 
METHODS. Secondary data analysis from a randomized controlled trial of PIVC dwell time. The Prentice, Williams, and Peterson statistical 
model was used to identify and compare risk factors for phlebitis, occlusion, and accidental removal. 
SETTING. Three acute care hospitals in Queensland, Australia. 
PARTICIPANTS. The trial included 3,283 adult medical and surgical patients (5,907 catheters) with a PIVC with greater than 4 days of 
expected use. 
RESULTS. Modifiable risk factors for occlusion included hand, antecubital fossa, or upper arm insertion compared with forearm (hazard 
ratio [HR], 1.47 [95% confidence interval (CI), 1.28-1.68], 1.27 [95% CI, 1.08-1.49], and 1.25 [95% CI, 1.04-1.50], respectively); and for 
phlebitis, larger diameter PIVC (HR, 1.48 [95% CI, 1.08-2.03]). PIVCs inserted by the operating and radiology suite staff had lower 
occlusion risk than ward insertions (HR, 0.80 [95% CI, 0.67-0.94]). Modifiable risks for accidental removal included hand or antecubital 
fossa insertion compared with forearm (HR, 2.45 [95% CI, 1.93-3.10] and 1.65 [95% CI, 1.23-2.22], respectively), clinical staff insertion 
compared with intravenous service (HR, 1.69 [95% CI, 1.30-2.20]); and smaller PIVC diameter (HR, 1.29 [95% CI, 1.02-1.61]). Female 
sex was a nonmodifiable factor associated with an increased risk of both phlebitis (HR, 1.64 [95% CI, 1.28-2.09]) and occlusion (HR, 1.44 
[95% CI, 1.30-1.61]). 
CONCLUSIONS. PIVC survival is improved by preferential forearm insertion, selection of appropriate PIVC diameter, and insertion by 
intravenous teams and other specialists. 
TRIAL REGISTRATION. The original randomized controlled trial on which this secondary analysis is based is registered with the Australian 
New Zealand Clinical Trials Registry (http://www.anzctr.org.au; ACTRN12608000445370). 
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Peripheral intravenous catheters (PIVCs) are the most fre- Many earlier studies and reviews have focused on the risk 
quently used invasive devices in acute care settings. Recent factors for phlebitis alone,1,912 have used composite mea-
studies document that 33%-67% of patients have a PIVC sures,10,13,14 or have selected only 2 specific causes of failure,7 
inserted during their hospitalization,1"3 and approximately and thus have not considered all major complications causing 
330 million devices are used in the United States each year.4 PIVC failure. In addition, the results of previous studies re-
Although some PIVCs are never used,5,6 and others are re- lated to risk factors for catheter failure have produced con-
moved when treatment ceases, many PIVCs are removed be- tradictory results (eg, variable direction of phlebitis risk as-
cause of complications. These complications include phle- sociated with sex).15"17 In this study, we sought to determine 
bitis, local infection, bloodstream infection, infiltration, the potentially modifiable factors associated with catheter fail-
occlusion, extravasation, and inadvertent removal.1,7"11 These ure, and so provide guidance for prevention of catheter fail-
lead to personal discomfort, increased medical treatment and ure, improvement in patient outcomes, and reduction in 
length of hospital stay, increased costs, and death.11 healthcare costs. 
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M E T H O D S 
This study used data from a large multicenter trial that com-
pared different regimens of PIVC replacement.18 Data were 
collected in 3 hospitals in Queensland, Australia, from May 
2008 to September 2009. Ethics committee approval was ob-
tained from Griffith University (NRS/07/08/HREC). All par-
ticipants gave written, informed consent before participation. 
Adult patients in medical and surgical units with PIVCs ex-
pected to be required for 4 or more days were randomized 
to third-daily routine replacement or replacement on clinical 
indication. Exclusion criteria were a current bloodstream in-
fection, planned PIVC removal within 24 hours, or PIVC 
already in situ for more than 72 hours. 
Of the 3 hospitals involved in the trial, the Royal Brisbane 
and Women's Hospital (RBWH) and the Princess Alexandra 
Hospital (PAH) are large metropolitan hospitals managing 
80,000 admissions per year (average length of stay, 6.5 days). 
The Gold Coast Hospital (GCH) is a large regional hospital 
which also has approximately 80,000 admissions a year but 
a shorter average length of stay (4.7 days). GCH did not have 
a PIVC insertion or monitoring service. The RBWH and PAH 
had PIVC insertion-only services that inserted approximately 
half of the catheters in the study. The remainder were inserted 
by general clinical staff. All study PIVCs were inserted into 
the upper limb. 
In total, 3,283 patients (accounting for 5,907 catheters) 
were enrolled. Baseline data were collected at the time of study 
entry and with every new catheter. Clinical staff cared for the 
catheters (Insyte and Autoguard; Becton Dickinson). Separate 
data were collected by trained research nurses who assessed 
patients daily for outcomes and a range of potential risk 
factors. Of the 5,907 catheters, 1,512 (25.6%) failed as a result 
of occlusion, 375 (6.4%) were accidentally removed, and 273 
(4.6%) were inserted in patients who developed phlebitis. 
D E F I N I T I O N S 
In this multivariate analysis, 3 separate catheter failure out-
comes were considered: (1) phlebitis; (2) occlusion (including 
infiltration, unintended iatrogenic leakage of fluids from vein 
into surrounding tissues, and obstruction of flow); and (3) 
accidental removal. Phlebitis was defined as the simultaneous 
presence of 2 or more of the following criteria: (1) pain and/ 
or tenderness with a severity of 2 or more on a 10-point scale 
(with 0 defined as no pain and 10 defined as the worst imag-
inable pain); (2) erythema extending to at least 1 cm from 
the insertion site; (3) swelling extending to at least 1 cm from 
the insertion site; (4) purulent discharge from the insertion 
site (dichotomous); and (5) a palpable venous cord beyond 
the tip of the catheter (dichotomous). 
Occlusion and accidental removal were the terms used by 
the clinical staff to describe failure when they removed a 
catheter. Occlusion was defined as any circumstance in which 
the PIVC was still in place but it was not possible to flush 
the catheter or infuse fluids (relatively synonymous terms 
include blockage, infiltration, extravasation, and "tissuing"). 
Accidental removal was defined as catheter dislodgement that 
was not planned. 
S T A T I S T I C A L ANALYSIS 
The outcomes of interest were time-dependent (survival data/ 
hazard rates); thus, Cox proportional hazards regression 
models were used for time-to-event analysis. Because multiple 
catheters per patient were studied, the conditional risk set 
model developed by Prentice, Williams, and Peterson (PWP)19 
was used, which extends the Cox model conditional on pa-
tients only being at risk of the ;'th event after the (j — 1 )th 
event occurs. All results reported in this article are based on 
the PWP model. All results are per PIVC, because per patient 
analyses were not appropriate to considering PIVC-related 
covariates that vary within patients. 
We prespecified potential patient-related, catheter-related, 
and healthcare-related risk factors for the risk models (in-
cluded in Table 1). Initially, bivariate associations were ex-
amined for the 3 outcomes and all possible covariates using 
time-adjusted rates. The 3 outcomes were (i) phlebitis, (ii) 
occlusion, and (iii) accidental removal. After bivariate anal-
yses, covariates were assessed in 3 separate multivariate mod-
els. The statistical software used for the analyses was StataSE 
12 (StataCorp). A 2-sided significance level of 5% was used 
throughout. 
Admission type, presence of a drain or stoma, receipt of 
oral antibiotics, and receipt of intravenous potassium were 
also tested but were not significantly associated with the 3 
outcomes and were not risk factors in the multivariate 
analyses. 
RESULTS 
The baseline characteristics of patients and PIVCs as well as 
their incidence against the 3 types of failure outcomes are 
presented in Table 1. The mean age of all subjects was 54.8 
years, with the mean age of patients with phlebitis being 51.6 
years (P< .01). There was no statistically significant difference 
in age associated with occlusion or accidental removal. 
Bivariate Analyses 
The bivariate analyses are shown in Table 1. Phlebitis was 
significantly associated with being female, being younger, hav-
ing a current infection, or currently receiving intravenous 
antibiotics. Significantly fewer cases of phlebitis were seen 
among those receiving "other" intravenous medications (ie, 
intravenous medications other than antibiotics, antipyretics, 
or hydrocortisone). 
Occlusion was significantly associated with being female; 
current infection; subsequent catheters compared with the 
first catheter; insertion in the antecubital fossa, hand, or up-
per arm compared with the forearm; and receiving intrave-
nous antibiotics. Significantly fewer cases of occlusion were 
seen with 18-gauge or larger catheters; insertion in the ra-
TABLE i. Baseline Clinical Characteristics and Crude Outcome Counts by Type of Catheter Failure 
Cases per 1,000 days (IRR, 95% CI) 
All catheters, % Occlusion Accidental removal Phlebitis 
Category (n = 5,907) (« = 1,512) (n = 375) (n = 273) 
Male (reference) 
Female 
No. of comorbidities 
0 (reference) 
1 
2 or more 
PIVC size 
20 gauge (reference) 
18 gauge or larger 
22 gauge or smaller 
Inserted by 
IV service (reference) 
Clinical staff 
Hospital 
A (reference) 
B 
C 
Inserted in 
Ward (reference) 
DEM 
OT/radiology 
Current infection 
No (reference) 
Yes 
Which PIVC 
First (reference) 
Second 
Third 
Fourth 
Fifth 
Insert in vein 
Forearm (reference) 
Antecubital fossa 
Hand 
Wrist 
Upper arm 
IV antibiotics 
No (reference) 
Yes 
IV antipyretic 
No (reference) 
Yes 
IV hydrocortisone 
No (reference) 
Yes 
IV "other" 
No (reference) 
Yes 
64.3 
35.7 
23.9 
21.4 
54.7 
55.4 
15.4 
29.2 
39.8 
60.2 
39.4 
35.7 
24.9 
77.1 
10.0 
12.9 
82.3 
17.7 
55.6 
25.0 
11.4 
5.3 
2.7 
54.5 
12.8 
22.4 
2.6 
7.7 
31.1 
68.9 
94.6 
5.4 
97.2 
2.8 
57.9 
42.1 
77.9 
104.5 
82.8 
89.9 
87.0 
88.0 
74.3 
91.2 
88.4 
85.5 
90.5 
80.7 
89.0 
89.4 
89.0 
72.8 
80.9 
113.7 
77.0 
99.9 
104.0 
101.9 
96.9 
78.6 
92.6 
102.1 
86.4 
99.6 
65.8 
96.3 
87.9 
67.5 
86.1 
106.6 
96.3 ( 
74.8 ( 
[1.00) 
[1.34, 1.21-1.49)" 
1.00) 
1.09, 0.93-1.27) 
1.05, 0.92-1.20) 
1.00) 
0.84, 0.72-0.98)" 
1.04, 0.92-1.16) 
J .00) 
;0.97, 0.87-1.07) 
1.00) 
0.89, 0.79-1.00) 
0.98, 0.86-1.12) 
1.00) 
1.00, 0.84-1.18) 
0.81, 0.69-0.96)" 
1.00) 
1.41, 1.24-1.59)a 
1.00) 
1.30, 1.15-1.47)a 
1.35, 1.15-1.59)" 
1.32, 1.05-1.65)" 
1.26, 0.92-1.68) 
1.00) 
1.18, 1.00-1.38)" 
1.30, 1.14-1.48)" 
1.10, 0.85-1.39) 
1.27, 1.05-1.52)" 
1.00) 
1.46, 1.30-1.65)" 
1.00) 
0.77, 0.60-0.97)" 
1.00) 
1.24, 0.92-1.64) 
1.00) 
0.78, 0.70-0.86)" 
21.8 
21.0 
26.2 
19.5 
20.4 
18.9 
27.0 
23.8 
12.8 
27.4 
12.7 
21.9 
36.8 
20.5 
23.7 
25.3 
21.9 
19.6 
22.0 
20.1 
19.4 
28.9 
15.8 
14.7 
29.2 
40.0 
21.9 
15.8 ( 
18.8 ( 
22.7 ( 
20.9 ( 
31.4 ( 
21.4 ( 
25.1 
19.2 ( 
24.3 ( 
(1.00) 
[0.97, 0.77-1.20) 
1.00) 
0.74, 0.54-1.02) 
0.78, 0.61-0.99)" 
1.00) 
1.43, 1.08-1.88)" 
1.26, 0.99-1.60) 
1.00) 
2.15, 1.69-2.76)" 
1.00) 
1.73, 1.31-2.27)* 
2.90, 2.22-3.80)" 
1.00) 
1.15, 0.81-1.61) 
1.23, 0.91-1.64) 
1.00) 
0.90, 0.67-1.18) 
1.00) 
0.91, 0.70-1.19) 
0.88, 0.60-1.26) 
1.31, 0.83-1.99) 
0.72, 0.31-1.44) 
1.00) 
1.99, 1.44-2.71)" 
2.72, 2.13-3.47)" 
1.49, 0.87-2.41) 
1.07, 0.65-1.68) 
1.00) 
1.21, 0.96-1.53) 
1.00) 
1.50, 1.02-2.15)" 
1.00) 
1.17, 0.60-2.07) 
1.00) 
1.26, 1.03-1.56)" 
13.4 
20.5 
16.1 
15.1 
15.6 
15.2 
18.6 
14.9 
15.1 
16.1 
15.3 
13.7 
19.0 
15.3 
21.4 
14.8 
14.4 
21.3 
14.0 
17.0 
18.3 
22.0 
17.8 
15.0 
15.8 
15.0 
17.3 
20.1 
11.8 
17.5 
15.8 
13.3 
15.5 
20.9 
18.0 ( 
12.8 ( 
(1.00) 
(1.51, 1.17-1.93)" 
(1.00) 
(0.94, 0.64-1.37) 
(0.97, 0.72-1.32) 
(1.00) 
(1.22, 0.88-1.68) 
(0.98, 0.73-1.31) 
(1.00) 
(1.06, 0.83-1.37) 
1.00) 
0.89, 0.67-1.20) 
1.24, 0.92-1.68) 
1.00) 
1.40, 0.96-2.00) 
0.97, 0.65-1.40) 
1.00) 
1.48, 1.10-1.96)" 
1.00) 
1.21, 0.89-1.63) 
1.30, 0.86-1.91) 
1.57, 0.92-2.53) 
1.27, 0.57-2.47) 
1.00) 
1.05, 0.70-1.55) 
1.00, 0.71-1.39) 
1.15, 0.63-1.96) 
1.34, 0.86-2.01) 
1.00) 
1.48, 1.12-1.99)" 
1.00) 
0.84, 0.45-1.44) 
1.00) 
1.35, 0.64-2.52) 
1.00) 
0.71, 0.55-0.91)" 
NOTE. CI, confidence interval; DEM, Department of Emergency Medicine; IRR, incidence rate ratio; IV, intravenous; OT, 
operating theater; PIVC, peripheral intravenous catheter. 
" P< .01 for bivariate association. 
" P < .05 for bivariate association. 
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TABLE 2. Independent Risk Factors for Phlebitis 
Risk factor 
Female sex 
Size 18 gauge or larger compared with size 20 gauge 
Current infection 
Age 
Other drugs infused through IV 
HR 
1.64 
1.48 
1.41 
0.99a 
0.72 
95% CI 
1.28-2.09 
1.08-2.03 
1.05-1.89 
0.98-0.99 
0.56-0.92 
P 
<.001 
.014 
.022 
<.001 
.009 
NOTE. Findings are from a multivariate Cox proportional hazards regression model 
with conditional risk sets that included phlebitis events as time-dependent covariates. 
CI, confidence interval; HR, hazard ratio; IV, intravenous catheter. 
a
 Increase in age by 1 year decreased the HR by 1.1%. 
diology or operating theater suite; or being prescribed oral risk was associated with insertion in the operating theater or 
antibiotics, intravenous antipyretics, or "other" intravenous radiology department and with intravenous antipyretic 
medications. infusion. 
Accidental removal was significantly associated with 18-
gauge or larger catheter size, insertion by clinical (non- Independent Risk Factors for Accidental Removal 
intravenous service) staff, hospital B or C, insertion in the „. ._ ,. . . , , , . , , , , , 
, j ^ L - . i r J - - . - r - J. Significant predictors of accidental removal included hand or 
hand or antecubital fossa, and injection of intravenous an- , . ,
 r • • • 
. . . . ., . . ,. .. „. -r ., antecubital fossa insertion, compared with the forearm; m-
tipyretics or other intravenous medications. Significantly . , . .
 rr . 
, c -J * i i • ^ J vi. i sertion by non-intravenous service start, and 22-gauge or 
lower rates of accidental removal were associated with mul- „ ' ,_,, . . . ,. r , 
.. , u ' j v J • • i ,.-L- 4.- smaller PIVC (Table 4). Practice comparison indicated that 
tiple comorbidities and receiving oral antibiotics. ' , 
intravenous service staff, compared with ward staff, inserted 
Independent Risk Factors for Phlebitis smaller catheters (20 gauge or smaller) more frequently (in-
travenous service, 98.2%; ward staff, 75.7%) and showed a 
Multivariate analysis demonstrated that phlebitis risk in-
 g r e a t e r p r e f e r e n c e for u s i n g t h e forearm m h e r t h a n t h e h a n d 
creased with younger age (each increased year of age de-
 ( i n t r a v e n o u s s e r v i c e > 7 0 > 6 % a n d 9 - 6 % > respectively; ward staff, 
creased the hazard ratio [HR] by 1.1%), being female, having
 4 L 9 % a n d 2 8 > 6 % > r e s t i v d } 
a larger catheter (18 gauge or larger), or current infection, 
whereas decreased risk was associated with infusion of "other" 
intravenous drugs (Table 2). 
This study confirms that larger catheter size (18 gauge or 
Independent Risk Factors for Occlusion , s ,. . , , , ... • . , . . .
 c •, 9U . 
r
 larger) predicts phlebitis-associated catheter failure but pro-
Table 3 outlines that significantly higher occlusion was as- vides new data to show that smaller catheter size (22 gauge 
sociated with insertion in the hand, antecubital fossa, or up- or smaller) predicts accidental removal. Current guidelines 
per arm compared with forearm; being female; infusion of do not recommend catheter size20,21 but could recommend 
antibiotics and/or hydrocortisone; current infection; and use preferential use of 20-gauge PIVCs, which are suitable for 
ofsubsequent rather than first catheters. Significantly reduced almost all infusion requirements. This study also confirmed 
TABLE 3. Independent Risk Factors for Occlusion 
Risk factor HR 95% CI P 
D I S C U S S I O N 
Hand compared with forearm 
Female sex 
Antibiotics infused through IV 
Hydrocortisone infused through IV 
Current infection 
Antecubital fossa compared with forearm 
Upper arm compared with forearm 
Second through fifth cannula compared with first cannula 
Inserted in OT/rad compared with ward 
Antipyretic infused through IV 
NOTE. Findings are from a multivariate Cox proportional hazards regression model 
with conditional risk sets that included occlusion events as time-dependent covariates. 
CI, confidence interval; HR, hazard ratio; IV, intravenous catheter; OT/rad, operating 
theater or radiology. 
1.47 
1.44 
1.41 
1.36 
1.27 
1.27 
1.25 
1.17 
0.80 
0.76 
1.28-1.68 
1.30-1.61 
1.25-1.59 
1.03-1.80 
1.12-1.44 
1.08-1.49 
1.04-1.50 
1.01-1.35 
0.67-0.94 
0.59-0.97 
<.001 
<.001 
<001 
.028 
<.001 
.004 
.016 
.037 
.009 
.030 
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TABLE 4. Independent Risk Factors for Accidental Removal 
Risk factor HR 95% CI 
Hand compared with forearm 
Insertion by clinical staff compared with IV service 
Antecubital fossa compared with forearm 
Size 22 gauge or smaller compared with 20 gauge 
2.45 
1.69 
1.65 
1.29 
1.93-3.10 
1.30-2.20 
1.23-2.22 
1.02-1.61 
<.001 
<.001 
.001 
.030 
NOTE. Findings are from a multivariate Cox proportional hazards regression 
model with conditional risk sets that included accidental removal events as time-
dependent covariates. CI, confidence interval; HR, hazard ratio; IV, intravenous. 
inser t ion site as a p red ic tor of phlebit is-associated catheter 
failure91216 but provides new data to show that site also pre-
dicts occlusion (the most common failure type). 
Current guideline site recommendations are limited to us-
ing the upper extremities,20 avoiding the wrist, and preferring 
distal areas.21 Updated guidelines should advise preferential 
forearm insertion and emphasize the importance of not rou-
tinely replacing catheters, because the first catheter is the least 
likely to fail. 
The use of an intravenous service reduced the risk of ac-
cidental removal, and insertion by other specialist staff re-
duced the risk of occlusion. Earlier studies support fewer 
instances of catheter failure with the use of intravenous ser-
vices,22,23 but only one of these studies was a randomized 
controlled trial (RCT).23 Additional RCTs are needed to un-
derstand optimal intravenous service models (eg, insertion 
only or including postinsertion management and/or training 
and surveillance). Extrapolating from our observed associa-
tions between intravenous infusion experts and their selection 
of catheter size and insertion site suggests other potentially 
effective interventions that need to be tested. These include 
approaches to training ward staff, the use of care bundles,24,25 
and the use of new dressings and sutureless securement 
devices.26,27 
Being female and having an infection were strong predic-
tors of both phlebitis and occlusion. Thus, staff should par-
ticularly target these high-risk groups for best-practice in-
sertion, monitoring and maintenance regimens. The 
increased risk of occlusion with antibiotic and hydrocortisone 
infusion suggests that improved dilution and flushing regi-
mens are needed; additional research in this area is warranted. 
Thus, clinical guidelines need to promote standardized in-
spection and flushing procedures, plus evidence-based dilu-
tion of infusates known to predispose to inflammation. 
The main strength of this study is that the data were col-
lected during a rigorous RCT with usual insertion and main-
tenance practices, thus ensuring generalizability; data collec-
tion by clinical trials nurses ensured that data were reliable.18 
Limitations include the lack of potentially important data on 
specific dressings; securement and flushing regimens; all med-
ications infused; and patient variables, such as body mass 
index, mobility, or cognitive status. 
In conclusion, these results indicate that having skilled staff 
insert 20-gauge catheters into the forearm and careful mon-
itoring and care of women and those receiving highly irritant 
infusates will maximize survival of PIVCs and decrease ad-
verse patient consequences. These factors will assist in de-
veloping education, policies, and guidelines related to PIVC 
insertion and management. Future research on optimal dress-
ing, securement, dilution, and flushing regimens as well as 
on models for dedicated intravenous teams needs to be un-
dertaken as a matter of urgency. 
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